3/19
07:21 am
acrv
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Medium
Report
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
3/17
06:16 pm
acrv
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors [Yahoo! Finance]
Low
Report
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors [Yahoo! Finance]
3/17
05:54 pm
acrv
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
Low
Report
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
3/3
01:47 pm
acrv
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why [Yahoo! Finance]
Medium
Report
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why [Yahoo! Finance]
3/2
09:02 pm
acrv
Acrivon Therapeutics (ACRV) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
High
Report
Acrivon Therapeutics (ACRV) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/1
01:10 am
acrv
Low
Report
2/27
12:00 pm
acrv
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer [Yahoo! Finance]
Medium
Report
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer [Yahoo! Finance]
2/24
08:33 am
acrv
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/24
08:00 am
acrv
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Neutral
Report
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2/23
08:00 am
acrv
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
Low
Report
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
2/21
02:04 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
2/18
08:00 am
acrv
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
Low
Report
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
1/28
09:15 am
acrv
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
Low
Report
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
1/23
08:11 am
acrv
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Low
Report
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
1/18
08:46 am
acrv
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares [Yahoo! Finance]
Low
Report
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares [Yahoo! Finance]
1/10
01:07 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St